Literature DB >> 923126

Transcranial approach for cancer of the antroethmoidal area.

P Clifford.   

Abstract

An improvement in the treatment results of antroethmoidal cancers may be achieved through the use of a transcranial approach, which makes an en bloc excision of the ethmoid labyrinths possible. This exposure allows dural involvement to be assessed, excised and repaired under direct vision. The technique used in the management of 9 patients is described. Eight of these patients presented with recurrent disease after previous radiotherapy and surgery. There were no deaths in the immediate postoperative period. Two patients are dead: one with disease in the frontal lobe; the other 18 months after operation, apparently free of disease. Facial deformity in patients who have undergone this operation is no greater than that associated with other operations in this area, and may be less, as a superior approach may allow the posterior ethmoidal and sphenoid area to be excised without orbital exenteration.

Entities:  

Mesh:

Year:  1977        PMID: 923126     DOI: 10.1111/j.1365-2273.1977.tb01611.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  4 in total

1.  Massive chondroma of skull base.

Authors:  N S Tanner; H J Shaw; P Clifford
Journal:  J R Soc Med       Date:  1979-08       Impact factor: 5.344

2.  Craniofacial resection for orbital tumours.

Authors:  A D Cheesman; R E Quiney; J E Wright
Journal:  Ann R Coll Surg Engl       Date:  1989-09       Impact factor: 1.891

Review 3.  Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review.

Authors:  Daniel B Spielman; Andi Liebowitz; Maeher Grewal; Chetan Safi; Jonathan B Overdevest; Alfred M Iloreta; Brett E Youngerman; David A Gudis
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2022-03-22

4.  Transcranial--facial approach for tumours of superior paranasal sinuses and orbit.

Authors:  P Clifford
Journal:  J R Soc Med       Date:  1980-06       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.